AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Tradingview

Published November 12, 2026

U.S. funding to support studies into psychedelic drug ibogaine in PTSD - TradingView

Read the full story at Tradingview

LSD , and MDMA. Leading psychedelic drug developers include Bright Minds Biosciences DRUG, COMPASS Pathways CMPS, GH Research GHRS, Definium.

Post on X

Share this story

Surfaced by 2 Google Alerts

LSD
Psychedelics